// App-Quantinova.ai

TPS596 : eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

Researchers

Presenter

  • Sara M. Tolaney

Principal Investigators

  • Lesley Fallowfield

  • Peter A. Kaufman

  • Eva M. Ciruelos

  • Mary Corona Gainford

  • Yi Lu

  • Karla Hurt

  • Heather Ann Wasserstrom

  • Yanyun Chen

  • Shom Goel

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • University of Sussex, London, United Kingdom

  • University of Vermont Medical Center and the Larner College of Medicine at UVM, Burlington, VT, University Hospital 12 de Octubre, Madrid, Spain

  • Sanofi Genzyme:*Former employee of Eli Lilly and Company, Boston, MA

  • Eli Lilly and Company, Indianapolis, IN, Peter MacCallum Cancer Centre, Melbourne, Australia

Locations

  • United Kingdom

  • Spain

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Abemaciclib

  • Trastuzumab

  • Pertuzumab

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacokinetics

  • Double Blind/Blinded

  • Superiority

  • Controlled

Phase

  • III

Study Id's

  • NCT04752332

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved